CSB 2.009 Note
961.16 (8) (c) Immediate precursors to phencyclidine, also known as PCP:
CSB 2.009 Note
1. 1-phenylcyclohexylamine.
CSB 2.009 Note
2. 1-piperidinocyclohexanecarbonitrile.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2021 No. 787, eff. 7-19-21; correction made under s.
35.17, Stats.,
Register July 2021 No. 787;
CR 22-040: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.009 Note
CSB 2.91 Addition of 4,4'-Dimethylaminorex to schedule I. Section
961.14 (7) (cm), Stats., is created to read:
CSB 2.009 Note
961.14 (7) (cm) 4,4'-Dimethylaminorex.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register September 2021 No. 789, eff. 9-27-21;
CR 22-054: cr.
Register June 2023 No. 810, eff. 7-1-23.
CSB 2.009 Note
CSB 2.92 Addition of thirty-five (35) Anabolic Steroids to schedule III. Section 961.18 (7), Stats., is repealed and recreated to read:
CSB 2.009 Note
961.18 (7) ANABOLIC STEROIDS. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation containing any quantity of any of the following anabolic steroids, including any of their esters, ethers, isomers, esters or ethers of isomers, salts and salts of esters or ethers, isomers and esters or ethers of isomers that are theoretically possible within the specific chemical designation. Except such terms do not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this section:
CSB 2.009 Note
(a) 3beta,17-dihydroxy-5alpha-androstane.
CSB 2.009 Note
(ag) 3alpha,17beta-dihydroxy-5alpha-androstane.
CSB 2.009 Note
(ar) 5alpha-androstan-3,17-dione.
CSB 2.009 Note
(b) 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-androst-1-ene).
CSB 2.009 Note
(bg) 4-androstenediol.
CSB 2.009 Note
(br) 5-androstenediol.
CSB 2.009 Note
(c) 1-androstenedione.
CSB 2.009 Note
(cg) 4-androstenedione.
CSB 2.009 Note
(cr) 5-androstenedione.
CSB 2.009 Note
(d) Bolasterone.
CSB 2.009 Note
(dg) Boldenone.
CSB 2.009 Note
(dr) Boldione.
CSB 2.009 Note
(e) Calusterone.
CSB 2.009 Note
(eg) 4-chlorotestosterone, which is also called clostebol.
CSB 2.009 Note
(er) Dehydrochloromethyltestosterone.
CSB 2.009 Note
(f) Desoxymethyltestosterone.
CSB 2.009 Note
(fg) Delta1-dihydrotestosterone.
CSB 2.009 Note
(fr) 4-dihydrotestosterone, which is also called stanolone.
CSB 2.009 Note
(g) Drostanolone.
CSB 2.009 Note
(gg) Ethylestrenol.
CSB 2.009 Note
(gr) Fluoxymesterone.
CSB 2.009 Note
(h) Formebulone, which is also called fromebolone.
CSB 2.009 Note
(hg) Furazabol.
CSB 2.009 Note
(hr) 13beta-ethyl-17beta-hydroxygon-4-en-3-one.
CSB 2.009 Note
(i) 4-hydroxytestosterone.
CSB 2.009 Note
(ig) 4-hydroxy-19-nortestosterone.
CSB 2.009 Note
(ir) Mestanolone.
CSB 2.009 Note
(j) Mesterolone.
CSB 2.009 Note
(jg) Methandienone, which is also called methandrostenolone.
CSB 2.009 Note
(jr) Methandriol.
CSB 2.009 Note
(k) Methasterone.
CSB 2.009 Note
(kg) Methenolone.
CSB 2.009 Note
(kr) 17alpha-methyl-3beta, 17beta-dihydroxy-5alpha-androstane.
CSB 2.009 Note
(L) 17alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane.
CSB 2.009 Note
(Lg) 17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene.
CSB 2.009 Note
(Lr) 17alpha-methyl-4-hydroxynandrolone.
CSB 2.009 Note
(m) Methyldienolone.
CSB 2.009 Note
(mg) Methyltestosterone.
CSB 2.009 Note
(mr) Methyltrienolone.
CSB 2.009 Note
(n) Mibolerone.
CSB 2.009 Note
(ng) 17alpha-methyl-delta1-dihydrotestosterone, which is also called 17-alpha-methyl-1-testosterone.
CSB 2.009 Note
(nr) Nandrolone.
CSB 2.009 Note
(o) 19-nor-4-androstenediol (3beta, 17beta-dihydroxyestr-4-ene; 3alpha, 17beta-dihydroxyestr-4-ene).
CSB 2.009 Note
(og) 19-nor-5-androstenediol (3beta, 17beta-dihydroxyestr-5-ene; 3alpha, 17beta-dihydroxyestr-5-ene).
CSB 2.009 Note
(or) 19-nor-4,9(10)-androstadienedione.
CSB 2.009 Note
(p) 19-nor-4-androstenedione (estr-4-en-3,17-dione).
CSB 2.009 Note
(pg) 19-nor-5-androstenedione (estr-5-en-3,17-dione).
CSB 2.009 Note
(pr) Norbolethone.
CSB 2.009 Note
(q) Norclostebol.
CSB 2.009 Note
(qg) Norethandrolone.
CSB 2.009 Note
(qr) Normethandrolone.
CSB 2.009 Note
(r) Oxandrolone.
CSB 2.009 Note
(rg) Oxymesterone.
CSB 2.009 Note
(rr) Oxymetholone.
CSB 2.009 Note
(s) Prostanozol.
CSB 2.009 Note
(sg) Stanozolol.
CSB 2.009 Note
(sr) Stenbolone.
CSB 2.009 Note
(t) Testolactone.
CSB 2.009 Note
(tg) Testosterone.
CSB 2.009 Note
(tr) Tetrahydrogestrinone.
CSB 2.009 Note
(u) Trenbolone.
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-018: cr.
Register April 2024 No. 820, eff. 5-1-24.
CSB 2.009 Note
CSB 2.93 Addition of Daridorexant to schedule IV. Section
961.20 (2) (cpm), Stats., is created to read:
CSB 2.009 Note
961.20 (2) (cpm) Daridorexant;
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-019: cr.
Register April 2024 No. 820, eff. 5-1-24; correction made under s.
35.17, Stats.,
Register April 2024 No. 820.
CSB 2.009 Note
CSB 2.94 Addition of seven (7) synthetic benzimidazole-opioid substances to schedule I. (1) Section 961.14 (2) (mm) and (pe), Stats., are renumbered to 961.14 (2) (xm) 3. and 5. and amended to read:
CSB 2.009 Note
961.14 (2) (xm) 3. Etonitazene (2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.009 Note
961.14 (2) (xm) 5. Isotonitazene (N,N -diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benizimidazol-1-yl)ethan-1-amine).
CSB 2.009 Note
961.14 (2) (xm) Synthetic Benzimidazole-opioid Substances, specifically including all of the following:
CSB 2.009 Note
1. Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.009 Note
2. Etodesnitazene also known as Etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.009 Note
4. Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5- nitro-1H-benzimidazol-1-yl)ethan-1- amine).
CSB 2.009 Note
6. Metodesnitazene (N,N-diethyl-2-(2-(4- methoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine).
CSB 2.009 Note
7. Metonitazene (N,N-diethyl-2-(2-(4- methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).
CSB 2.009 Note
8. N-pyrrolidino etonitazene also known as etonitazepyne (2-(4-ethoxybenzyl)-5-nitro-1-(2- (pyrrolidin-1-yl)ethyl)-1H-benzimidazole).
CSB 2.009 Note
9. Protonitazene (N,N-diethyl-2-(5-nitro-2-(4- propoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine).
CSB 2.009 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction in numbering of (1), (2) made under s.
13.92 (4) (b) 1., Stats., and correction in (1) made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-020: cr.
Register April 2024 No. 820, eff. 5-1-24; correction made under s.
35.17, Stats.,
Register April 2024 No. 820.
CSB 2.009 Note
CSB 2.95 Addition of Ganaxolone to schedule V. Section
961.22 (11), Stats., is created to read:
CSB 2.009 Note
961.22 (11) Ganaxolone. Ganaxolone.
